Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ).
Sichuan Kelun-Biotech has received Investigational New Drug approval from China’s National Medical Products Administration for SKB105 (CR-003), an internally developed integrin beta-6–targeted antibody-drug conjugate for the treatment of advanced solid tumors, enabling the company to advance this differentiated oncology asset into clinical development. The company also highlighted its strategic collaboration with Crescent Biopharma, under which Crescent holds ex-China rights to SKB105/CR-003 and Kelun-Biotech retains Greater China rights while gaining Greater China rights to SKB118/CR-001, a PD-1 x VEGF bispecific antibody for solid tumors, positioning the company to build a complementary oncology portfolio and expand its presence in both domestic and global cancer therapeutics markets.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$545.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a China-based biopharmaceutical company focused on developing innovative oncology therapies, including antibody-drug conjugates (ADCs) and bispecific antibodies. Its pipeline targets advanced solid tumors, with a geographic strategy that leverages partnerships to access markets outside Greater China while retaining commercialization rights domestically.
Average Trading Volume: 615,330
Technical Sentiment Signal: Buy
Current Market Cap: HK$93.41B
For detailed information about 6990 stock, go to TipRanks’ Stock Analysis page.